Literature DB >> 11593830

Proton pump inhibitors: perspectives of patients and their GPs.

J Grime1, K Pollock, A Blenkinsopp.   

Abstract

BACKGROUND: There is growing concern with the rapid increase in prescribing proton pump inhibitor drugs (PPIs) for a variety of gastrointestinal disorders, and the escalating costs associated with this trend. Explanations have included that general practitioners (GPs) prescribe PPIs inappropriately and that patients demand PPIs and use them as a way of avoiding having to make lifestyle changes. AIM: To compare the perspectives of GPs and their patients on the need for PPIs, to examine the pressure to prescribe, and to examine the effect of PPIs on lifestyle. DESIGN OF STUDY: Qualitative comparative study based on semi-structured interviews.
SETTING: Twenty-six GPs in seven practices in the West Midlands and 82 of their patients on repeat prescriptions for PPIs.
METHOD: Interviews were conducted covering a wide range of topics, including: experience, cause, course, and outcome of stomach problems; effectiveness of PPIs; and role of lifestyle in controlling symptoms. The transcripts were studied repeatedly to look for the occurrence and distribution of material relating to these issues, as well as other responder-driven issues. Codebooks were devised to enable a simple categorisation and systematic comparison of cases.
RESULTS: GPs and patients agreed about the severity and unpleasantness of stomach symptoms for which PPIs were prescribed. While GPs and patients regarded PPIs as a very effective treatment, GPs rated their efficacy more highly than patients. Half of the GP interviews reproduced the stereotype of the demanding patient and of patients using PPIs to support unhealthy lifestyles. There was little evidence from patient interviews to support either stereotype. Doctors underestimated patient concerns about side-effects, safety, and long-term use of PPIs, and the willingness of patients to achieve the minimum effective dose by experimenting with their treatment. GPs felt that the pressure to prescribe PPIs was outweighed by the pressure not to prescribe, and most GPs had responded to the call to cut the prescribing of PPIs. Different strategies were employed to cut prescribing, including the wholesale switching of patients on a treatment dose of one brand of PPI to a maintenance dose of a cheaper brand of PPI, known as 'double switching'.
CONCLUSION: The stereotypes of 'profligate prescriber', 'demanding patient', and 'adverse lifestyle', as explanations for the increase in the prescribing of PPIs, were not upheld. The stereotype of patients demanding PPIs may arise from GPs' internal pressure to prescribe being externalised onto patients. The extent to which health behaviour contributes to gastric disorders needs to be established empirically. Labelling PPI patients as having a poor lifestyle may be used as a means of reducing legitimate need for PPIs. Current policy relating to switching of dose and brand of PPI should be reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593830      PMCID: PMC1314097     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  10 in total

1.  Physician motivations for nonscientific drug prescribing.

Authors:  R K Schwartz; S B Soumerai; J Avorn
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

Review 2.  Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases?

Authors:  S Holt
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

3.  Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before these drugs are started.

Authors:  S M Griffin; S A Raimes
Journal:  BMJ       Date:  1998-12-12

4.  The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey.

Authors:  N Britten; O Ukoumunne
Journal:  BMJ       Date:  1997-12-06

5.  Pressures on the general practitioner and decisions to prescribe.

Authors:  M C Weiss; R Fitzpatrick; D K Scott; M J Goldacre
Journal:  Fam Pract       Date:  1996-10       Impact factor: 2.267

6.  Proton-pump inhibitors: three of a kind?

Authors:  D N Bateman
Journal:  Lancet       Date:  1997-06-07       Impact factor: 79.321

7.  Guidelines for dyspepsia management in general practice using focus groups.

Authors:  A P Hungin; G P Rubin; A J Russell; B Convery
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

8.  Patients' demands for prescriptions in primary care.

Authors:  N Britten
Journal:  BMJ       Date:  1995-04-29

9.  Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self-regulation of treatment may be an under-exploited resource.

Authors:  K Pollock; J Grime
Journal:  Soc Sci Med       Date:  2000-12       Impact factor: 4.634

10.  Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.

Authors:  J N Bashford; J Norwood; S R Chapman
Journal:  BMJ       Date:  1998-08-15
  10 in total
  10 in total

1.  Patients' views on cost effectiveness of drugs are important.

Authors:  K Pollock; J Grime
Journal:  BMJ       Date:  2000-11-18

2.  Inappropriate prescribing of proton pump inhibitors in primary care.

Authors:  Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett
Journal:  Postgrad Med J       Date:  2007-01       Impact factor: 2.401

3.  When does testing for GERD become cost effective in an integrated health network?

Authors:  Anoop Raman; Joel Sternbach; Azeesat Babajide; Ketan Sheth; Steven D Schwaitzberg
Journal:  Surg Endosc       Date:  2009-12-09       Impact factor: 4.584

4.  Should I continue taking my acid reflux medication? Design of a pilot before/after study evaluating a patient decision aid.

Authors:  Wade Thompson; Barbara Farrell; Vivian Welch; Peter Tugwell; Lise M Bjerre
Journal:  Can Pharm J (Ott)       Date:  2016-11-30

Review 5.  Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review.

Authors:  Wade Thompson; Cody Black; Vivian Welch; Barbara Farrell; Lise M Bjerre; Peter Tugwell
Journal:  Patient       Date:  2018-02       Impact factor: 3.883

Review 6.  Patient barriers to and enablers of deprescribing: a systematic review.

Authors:  Emily Reeve; Josephine To; Ivanka Hendrix; Sepehr Shakib; Michael S Roberts; Michael D Wiese
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

Review 7.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Authors:  Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell
Journal:  Cochrane Database Syst Rev       Date:  2017-03-16

8.  Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors.

Authors:  Pauline Siew Mei Lai; Yin Yen Wong; Yong Chia Low; Hui Ling Lau; Kin-Fah Chin; Sanjiv Mahadeva
Journal:  PeerJ       Date:  2014-06-26       Impact factor: 2.984

9.  General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study.

Authors:  P F Haastrup; S Rasmussen; J M Hansen; R D Christensen; J Søndergaard; D E Jarbøl
Journal:  BMC Fam Pract       Date:  2016-05-28       Impact factor: 2.497

10.  Patient Awareness of Reported Adverse Effects Associated with Proton Pump Inhibitors in a Medically Underserved Community.

Authors:  Brian White; Matthew Drew; John Gaughan; Sangita Phadtare
Journal:  Healthcare (Basel)       Date:  2020-11-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.